- News>
- India
PM Narendra Modi hails DCGI vaccine nod, says `move will lead to COVID-free nation`
The Serum Institute of India, the world`s largest vaccine manufacturer, has tied up with Oxford-AstraZeneca to manufacture Covishield.
Highlights
- DCGI on Sunday approved Covishield and Covaxin for restricted use in India.
- Covaxin is developed by Bharat Biotech.
- Serum Intitute and Bharat Biotech vaccines have to be administered in two doses.
NEW DELHI: Prime Minister Narendra Modi on Sunday (January 3) hailed the Drugs Controller General of India (DCGI)'s nod for Serum Institute's Covishield and Bharat Biotech's Covaxin for restricted use in India. The Prime Minister termed the move as a decisive turning point in the country’s fight against the virus and expressed his gratitude for all frontline workers in 'adverse circumstances'.
In a series of tweets, Prime Minister Modi congratulated Serum Institute and Bharat Biotech on getting the DCGI’s approval. "A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators. DCGI approves restricted emergency use of Serum Institute, Bharat Biotech's COVID-19 vaccines," PM Modi said.
"It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfill the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion," PM Modi said in a another tweet.
The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with Oxford-AstraZeneca to manufacture Covishield. Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Serum Institute of India's CEO Adar Poonawalla tweeted, "Happy new year, everyone! All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks."
The approval by the DCGI was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). This paves the way for the roll out of at least two vaccines in India in the coming days.